This has been one of those weeks where I spent some time thinking about taking risks in science. How much risk one should take? Risks can come in many forms. It could be at the core level at the bench doing specific experiments and not others. There’s risk in clinical trials, and even in advocacy. Sometimes …
Weekly science reads: Macchiarini trial, somites, CRISPR babies Read More »
It seems like the field of cell biology has mixed feelings about fibroblasts so I’m going to start off there with the recommended reads. But first, check out our stem cell YouTube channel as we are steadily heading toward 500 subscribers and 30,000 views. Please subscribe. I’ve pasted one of our top videos below, which …
Weekly reads: fibroblasts, cancer stem cells, Parkinson’s Read More »
How much promise is there today for stem cell therapy for heart disease? Where do things stand with the clinical research? Patients regularly ask me these kinds of questions. The goal of today’s post is to update you on where things stand. What’s in this post Stem Cell Therapy | Clinical Trials | Delivery of …
Stem cell therapy for heart disease: what you need to know Read More »
Science must go on and so must stem cell meetings in 2022 with all those great conferences out there, but hopefully this year will be better than 2020-2021. It seems that way with the pandemic easing in the U.S. and many other places. On the other hand, COVID is spiking in Asia and other regions. …
Hub of Regenerative Medicine & Stem Cell Meetings 2022 Read More »
Stem cell research relies on some unusual reagents at times including a cell culture product called Matrigel. One of the challenges with such reagents is that if they suddenly are back-ordered it could bring some research to a halt. Matrigel has been in short supply for the last year or so. These products also tend …
What is Matrigel, why a shortage, & alternatives? Read More »
Not everything in biomedical science is a ground-breaking discovery or clinical game-changer, but CAR-T cell technology is a combination of both. CAR-T cell good news We have such good news in this new pub on long-term benefits: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells, Nature. Another recent CAR-T cell article, this one in Science, …
Weekly reads: CAR-T cell good news, Califf fight, stem cells on lymph Read More »
When we hear the word senile we might think stereotypically of an older person who has cognitive impairment, but some argue that senility can apply to cells too as they age and that such cells can be targeted by drugs called senolytics. Unfortunately, the supplements industry has picked up on this idea to sell iffy …
Recommended reads: senolytics, cow iPS cells, big CIRM royalty Read More »
The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I …
Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »
Is 2022 going to be any better than 2020 or 2021 when it comes to things in general or for biomedical science? Related to the pandemic? It’s too soon to say but if I had to guess right now I’d venture an optimistic view that overall it’s going to be somewhat better by the end …
Weekly science reads: senescence, alt CRISPR, sickle cell update Read More »
Happy New Year and get ready for another 364 more days of stem cell excitement and craziness in 2022. In the next day or two I’ll post my predictions for this new year. Recommended reads EO Wilson obit by Carl Zimmer in NYT. Who’s the next EO Wilson or someone like him with such big impact these …
Weekly stem cell reads: COVID kidney, FDA letter, H3.3, EO Wilson Read More »